Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2007Cited by 163 (Europe PMC)

PMID17042738DOI10.1359/jbmr.061011PepBankPUB-17042738

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, finite element analysis of QCT scans showed greater median increases in average volumetric density with teriparatide than alendronate.
In plain wordsIn women with osteoporosis, average bone density on scans rose more with teriparatide than with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAverage volumetric density
Study
n = 53
Finite element models of lumbar vertebra QCT scans
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (Human).
Source sentences
Summary
Patients in both treatment groups had increased average volumetric density and increased strength in the trabecular bone, but the median percentage increases for these parameters were 5- to 12-fold greater for TPTD.
3 context sentences(design, population, supporting numbers)
Summary · context
A subset of patients (N = 28 TPTD; N = 25 ALN) from the Forteo Alendronate Comparator Trial who had QCT scans of the spine at baseline and postbaseline were analyzed.
Summary · context
The QCT scans were analyzed for compressive strength of the L(3) vertebra using FE modeling.
Summary · context
Teriparatide 20 microg/day (TPTD) and alendronate 10 mg/day (ALN) increase areal, measured by DXA, and volumetric, measured by QCT, lumbar spine BMD through opposite effects on bone remodeling.
Report a problemFND-1704273802
02Computer modelIn silicoEfficacy outcome
Finite element models showed greater median increases in trabecular strength with teriparatide than alendronate.
In plain wordsIn computer models, trabecular bone strength increased more with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone strength
Study
n = 53
Finite element models of lumbar vertebra QCT scans
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Patients in both treatment groups had increased average volumetric density and increased strength in the trabecular bone, but the median percentage increases for these parameters were 5- to 12-fold greater for TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
A subset of patients (N = 28 TPTD; N = 25 ALN) from the Forteo Alendronate Comparator Trial who had QCT scans of the spine at baseline and postbaseline were analyzed.
Summary · context
The QCT scans were analyzed for compressive strength of the L(3) vertebra using FE modeling.
Report a problemFND-1704273803
03Computer modelIn silicoEfficacy outcome
Finite element models showed larger increases in the strength:density ratio with teriparatide than alendronate, primarily through trabecular strength.
In plain wordsIn computer models, the strength to density ratio increased more with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseStrength to density ratio
Study
n = 53
Finite element models of lumbar vertebra QCT scans
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Larger increases in the strength:density ratio were also observed for TPTD, and these were primarily attributed to preferential increases in trabecular strength.
2 context sentences(design, population, supporting numbers)
Summary · context
A subset of patients (N = 28 TPTD; N = 25 ALN) from the Forteo Alendronate Comparator Trial who had QCT scans of the spine at baseline and postbaseline were analyzed.
Summary · context
The QCT scans were analyzed for compressive strength of the L(3) vertebra using FE modeling.
Report a problemFND-1704273804
04Computer modelIn silicoEfficacy outcome
Finite element models showed increased vertebral strength in at least 75% of teriparatide-treated patients at 6 months versus baseline.
In plain wordsIn computer models from teriparatide-treated scans, vertebral strength increased compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePredicted vertebral strength
Study
n = 28
Finite element models of lumbar vertebra QCT scans
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
At least 75% of the patients in each treatment group had increased strength of the vertebra at 6 months compared with baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
A subset of patients (N = 28 TPTD; N = 25 ALN) from the Forteo Alendronate Comparator Trial who had QCT scans of the spine at baseline and postbaseline were analyzed.
Summary · context
The QCT scans were analyzed for compressive strength of the L(3) vertebra using FE modeling.
Report a problemFND-1704273801

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.